Publications in collaboration with researchers from Instituto Universitario de Oncologia del Principado de Asturias (20)

2024

  1. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma

    eBioMedicine, Vol. 102

2023

  1. Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling

    Biomedicine and Pharmacotherapy, Vol. 162

  2. Cold plasma and inhibition of STAT3 selectively target tumorigenicity in osteosarcoma

    Redox Biology, Vol. 62

  3. Cold plasma-treated medium preferentially eliminates doxorubicin-resistant osteosarcoma cells

    Free Radical Biology and Medicine, Vol. 209, pp. 127-134

  4. Exploring the Use of Cold Atmospheric Plasma to Overcome Drug Resistance in Cancer

    Biomedicines, Vol. 11, Núm. 1

2022

  1. Addressing Doxorubicin Resistance in Bone Sarcomas using Novel Drug‐Resistant Models

    International Journal of Molecular Sciences, Vol. 23, Núm. 12

  2. Cold atmospheric plasma enhances doxorubicin selectivity in metastasic bone cancer

    Free Radical Biology and Medicine, Vol. 189, pp. 32-41

  3. Proof of concept for the use of trained sniffer dogs to detect osteosarcoma

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Mithramycin delivery systems to develop effective therapies in sarcomas

    Journal of Nanobiotechnology, Vol. 19, Núm. 1

2019

  1. New chondrosarcoma cell lines with preserved stem cell properties to study the genomic drift during in vitro/in vivo growth

    Journal of Clinical Medicine, Vol. 8, Núm. 4

  2. Pyruvate Plays a Main Role in the Antitumoral Selectivity of Cold Atmospheric Plasma in Osteosarcoma

    Scientific Reports, Vol. 9, Núm. 1

  3. The multikinase inhibitor EC-70124 synergistically increased the antitumor activity of doxorubicin in sarcomas

    International Journal of Cancer, Vol. 145, Núm. 1, pp. 254-266

2018

  1. FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway

    Neoplasia (United States), Vol. 20, Núm. 1, pp. 44-56

2017

  1. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models

    Neoplasia (United States), Vol. 19, Núm. 6, pp. 460-470

2016

  1. Aldh1 Expression and Activity Increase during Tumor Evolution in Sarcoma Cancer Stem Cell Populations

    Scientific Reports, Vol. 6

  2. Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma

    Oncotarget, Vol. 7, Núm. 21, pp. 30935-30950

  3. Osteosarcoma: Cells-of-Origin, Cancer stem cells, and targeted therapies

    Stem Cells International, Vol. 2016

2015

  1. Bone microenvironment signals in osteosarcoma development

    Cellular and Molecular Life Sciences, Vol. 72, Núm. 16, pp. 3097-3113

2014

  1. Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells

    Stem Cells, Vol. 32, Núm. 5, pp. 1136-1148

2013

  1. Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation

    Stem Cells, Vol. 31, Núm. 10, pp. 2061-2072